成人晚期急性B淋巴细胞白血病的免疫治疗  

Immune therapy of advanced B-cell acute lymphoblastic leukaemia in adults

作　　者：Robert Peter GaleDavid Kegyes Ciprian Jitaru Ciprian Tomuleasa Robert Peter GaleDavid Kegyes;Ciprian Jitaru;Ciprian Tomuleasa(Centre for Haematology,Imperial College of Science,Technology and Medicine,London,UK;Department of Hematology-Medfuture Research Center for Advanced Medicine,Iuliu Haţieganu University of Medicine and Pharmacy Cluj Napoca,Romania;Department of Hematology,Ion Chiricuta Oncology Institute,Cluj Napoca,Romania)

机构地区：[1]英国伦敦帝国理工学院血液学中心 [2]罗马尼亚鲁里欧·哈提甘努医药大学血液学-医学未来高级医学研究中心 [3]罗马尼亚克卢日纳波卡Ion Chiricuta肿瘤研究所血液学系

出　　处：《临床血液学杂志》2025年第3期161-165,共5页Journal of Clinical Hematology

摘　　要：成人急性B淋巴细胞白血病(acute B-cell lymphoblastic leukaemia,B-ALL)患者中部分人群尚无法通过现有疗法获得治愈,新近批准的数款免疫疗法在该群体中显示安全有效。本述评旨在对晚期成人B-ALL免疫疗法的临床研究数据进行概要总结,包括利妥昔单抗、贝林妥欧单抗、奥加伊妥珠单抗、替沙仑赛、brexucabtagene autoleucel和obecabtagene autoleucel。Many adults with acute B-cell lymphoblastic leukaemia(B-ALL)are not cured by current therapies.However,several newly-approved immune therapies are safe and effective in this setting.We summarize data on immune therapies of advanced adult B-cell ALL including rituximab,blinatumomab,inotuzumab ozogamicin,tisagenlecleucel,brexucabtagene autoleucel and obecabtagene autoleucel.

关 键 词：急性B淋巴细胞白血病 急性淋巴细胞白血病 免疫疗法 贝林妥欧单抗 奥加伊妥珠单抗 替沙仑赛 brexucabtagene autoleucel 

分 类 号：R733.71[医药卫生—肿瘤]